Mutation pattern of lamivudine resistance in relation to hepatitis B genotypes: Hepatitis B genotypes differ in their lamivudine resistance associated mutation pattern

Authors

  • Hans Damerow,

    1. Department of Internal Medicine, Neurology and Dermatology, Clinic for Gastroenterology and Rheumatology, University of Leipzig, Leipzig, Germany
    Search for more papers by this author
  • Lilly Yuen,

    1. Victorian Infectious Diseases Reference Laboratory, North Melbourne, Victoria, Australia
    Search for more papers by this author
  • Johannes Wiegand,

    1. Department of Internal Medicine, Neurology and Dermatology, Clinic for Gastroenterology and Rheumatology, University of Leipzig, Leipzig, Germany
    Search for more papers by this author
  • Christine Walker,

    1. Department of Molecular Pathology, Institute for Pathology, University of Tübingen, Tübingen, Germany
    Search for more papers by this author
  • C.-Thomas Bock,

    1. Department of Molecular Pathology, Institute for Pathology, University of Tübingen, Tübingen, Germany
    2. Robert Koch-Institute, Berlin, Germany
    Search for more papers by this author
  • Stephen Locarnini,

    1. Victorian Infectious Diseases Reference Laboratory, North Melbourne, Victoria, Australia
    Search for more papers by this author
  • Hans L. Tillmann

    Corresponding author
    1. Department of Internal Medicine, Neurology and Dermatology, Clinic for Gastroenterology and Rheumatology, University of Leipzig, Leipzig, Germany
    2. Duke Clinical Research Institute, Duke University, Durham, North Carolina
    • Assistant Professor, Duke Clinical Research Institute, 2400 Pratt Street, Duke University Medical Center, Box 17969, Durham, NC 27705.
    Search for more papers by this author

  • Hans Damerow, Lilly Yuen, C.-Thomas Bock, Stephen Locarnini, and Hans L. Tillmann contributed equally to this work.

Abstract

Little is known about differences between individual hepatitis B genotypes and mutation patterns associated with lamivudine resistance. This study analyses the lamivudine-associated mutation pattern in relation to the four major HBV genotypes A–D. The PubMed database was screened for keywords “HBV OR Hepatitis B,” “YMDD,” “genotype,” and “lamivudine”; all identified publications published till June 2009 were analyzed for differences in mutation pattern. To confirm the literature-based findings the databases of two reference laboratories in Tübingen (Germany), and Melbourne (Australia) were analyzed. Twenty-nine studies were identified reporting 827 patients with known hepatitis B genotype who underwent lamivudine treatment and developed resistance mutations. The literature data revealed that genotype A favors the rtM204V mutation unlike the other major genotypes (P < 0.001), which corresponds to a significant difference in the mutation pattern of genotypes endemic in Asian countries and those found in the rest of the world. These significant findings of the literature-review could be reproduced in the analysis of the databases from Tübingen and Melbourne. Furthermore, the rtL180M mutation is significantly connected to the rtM204V mutation in genotypes A, B, and C, respectively. It is concluded that there is proof that HBV genotypes differ in their mutation pattern of lamivudine resistance. Future studies will need to evaluate whether this will translate into genotype-specific differences in resistance emergence on either entecavir or telbivudine as these antivirals differ in their mutation profile, rtM204V for entecavir and rtM204I for telbivudine. J. Med. Virol. 82:1850–1858, 2010. © 2010 Wiley-Liss, Inc.

Ancillary